UNITED THERAPEUTICS CORP

Martine Rothblatt’s recent 10(b)(5)(1) trades at United Therapeutics show disciplined insider buying and selling, keeping a 10% stake while managing risk and signaling confidence in the company’s pipeline.

Insightful analysis of United Therapeutics insider trades shows disciplined 10b‑5‑1 buying at deep discounts and strategic selling, highlighting management confidence and risk‑management practices.

Explore how United Therapeutics’ CFO insider trades reinforce governance, pricing power and pipeline confidence for investors.

Insightful look at United Therapeutics’ CEO insider trades under a 10b5‑1 plan – balancing liquidity with confidence in the company’s pipeline and valuation.

CEO Martine Rothblatt’s 10b5‑1 buys and sales at United Therapeutics reveal strategic confidence in an undervalued stock, offering investors insight into the company’s pipeline and future prospects.

Insightful overview of United Therapeutics’ CFO insider trades, highlighting strategic liquidity use for R&D, debt management, and future partnership prospects.

CEO’s June 8 buy of United Therapeutics at $146 shows insider confidence in the company’s prostacyclin pipeline, while her sales reflect routine tax‑planning—an intriguing signal for investors.

Discover how United Therapeutics’ insider trades reveal CEO confidence, strong pipeline growth, and strategic R&D funding that supports long‑term value.

Discover how United Therapeutics’ insider trades reveal a disciplined strategy, diverse pipeline, and partnership‑driven growth in biotech.

Insightful UTX insider trades reveal a disciplined, plan‑based approach, boosting investor confidence while maintaining stable share prices and long‑term growth prospects.